Abstract
Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have